Efficacy and Safety of Combination Therapy of Zinc and Silver Oxide Nanoparticles in Streptozotocin-Induced Diabetic Rats

In the present study, Zinc oxide nanoparticles andSilver Oxide nanoparticles were evaluated for their in vivo and in vitro antidiabetic activity. The resulting ZnO, Ag₂O were characterized via various methods like UV, XRD, FTIR, PSA and SEM, TEM, and ICP-OES. The synthesized NPs were tested sub-acute oral toxicity model by abiding by the OECD425 guidelines. The male Wistar rats with a weight ranging from 180-200 g were grouped as follows: normal control: those that didn’t received any treatment, Diabetic control: who received a single intraperitoneal dose of streptozotocin (45mg kg ^-1), Zinc Oxide Nanoparticles: received single daily oral dose of (30mg kg^-1), Silver Oxide Nanoparticles: received a single daily oral dose of (30mg kg^-1) Combine Zinc Oxide and Silver Oxide Nanoparticles (60mg kg^-1). Metformin received a single daily oral dose of 100mg kg^-1. Synthesized Zn and Ag₂O nanoparticles showed no toxic effect and were considered safe. From the experimental results, it may be concluded that the combined dose of ZnO and Ag₂O had more potent antihyperglycemic activity, further studies are required to establish the mechanism of action.